The effects of the synthetic cannabinoid WIN 55,212-2 on heat-evoked firing of spinal wide dynamic range (WDR) neurons were examined in a rodent model of neuropathic pain. Fifty-eight WDR neurons (1 cell/animal) were recorded from the ipsilateral spinal dorsal horns of rats with chronic constriction injury (CCI) and sham-operated controls.
INTRODUCTION
Chronic constriction of the sciatic nerve (CCI) in rats, which mimics persistent nerve entrapment (Bennett and Xie, 1988) , is a widely used model of neuropathic pain. CCI rats show symptoms that are common in human neuropathic pain patients including allodynia, mechanical and thermal hyperalgesia, extraterritorial pain and guarding behavior suggestive of spontaneous pain (Bennett and Xie, 1988; Attal et al., 1990) .
Electrophysiological studies revealed that spinal dorsal horn neurons ipsilateral to the constricted nerve become sensitized, this manifested by increased spontaneous activity, exaggerated responses to afferent input and prolonged afterdischarge to noxious stimuli (Palececk et al., 1992; Sotgiu et al., 1992; Laird and Bennett, 1993) . One advantage of this experimental model lies in the possibility of correlating behavioral signs of pain with physiological changes that occur in the nerve itself or its central connections.
Cannabinoids suppress pain reactions in animal models of acute pain, an early example being that of Dixon (1899) who observed that dogs failed to respond to pinpricks following exposure to cannabis smoke. The subsequent preclinical literature is uniform in showing that naturally occurring cannabinoids (e.g., 9 -tetrahydrocannabinol) and synthetic cannabinoids (e.g., WIN 55, 940 ) inhibit responses to all types of acute noxious stimuli (Sofia et al., 1973; Lichtman and Martin, 1991; Welch et al., 1998; Martin et al., 1996; Smith et al., 1998) . While the profound suppression of pain behavior by cannabinoids is impressive, cannabinoids also produce motor dysfunction which could be misinterpreted as a loss of sensory responsiveness (reviewed in Sañudo-Peña et al., 1998) . However, neurophysiological studies showed that cannabinoids suppress the responsiveness of nociceptive neurons in the spinal cord and thalamus indicating a reduction in nociceptive processing independent of any motor effects (Hohmann et al., 1995 (Hohmann et al., , 1998 (Hohmann et al., , 1999b Hohmann & Walker, 1999; Martin et al., 1996; Strangman & Walker, 1999) .
Cannabinoids are also effective against persistent nociceptive processes, reducing the spontaneous pain behavior as well as the hyperalgesia and allodynia that result from noxious chemical stimuli and peripheral inflammation (Bicher and Mechoulam 1968;  Page 3 of 41 Kosersky et al. 1973; Moss and Johnson, 1980; Tsou et al., 1996 . Richardson et al., 1998 Martin et al., 1999 , Li et al., 1999 . Herzberg et al. (1997) reported that relatively low doses of the cannabinoid agonist WIN 55,212-2 eliminated the hyperalgesia and allodynia produced by CCI, a finding confirmed by others (Bridges et al. 2001; Fox et al. 2001 ). Both CB1 (Herzberg et al., 1997; Mao et al., 2000; Bridges et al., 2001; Fox et al., 2001) and CB2 (Malan et al., 2003; Ibrahim et al., 2005; Elmes et al., 2004; Sagar et al., 2005) receptors at peripheral and central sites were proposed to mediate cannabinoidinduced antinociception sites in neuropathic pain..
To gain insight into the mechanisms by which cannabinoids suppress neuropathic pain, we used electrophysiological methods to examine the effects of WIN 55,212-2 (0.0625, 0.125 and 0.25 mg /ml, i.v.) on spontaneous and heat-evoked activity of lumbar dorsal horn neurons and their receptive field sizes in the CCI model of neuropathic pain.
Subtype-specific cannabinoid receptor antagonists were used to determine the whether the observed effects were mediated by CB 1 or CB 2 receptors. The relationships between the neurophysiological and behavioral effects of the drug were studied to provide insight into the neurophysiological parameters that predict pain behavior.
MATERIALS AND METHODS

Drug preparation
The mixed CB 1 /CB 2 cannabinoid agonist WIN 55, 212-2 (Research Biochemicals International, Natick, MA), the CB 1 antagonists SR141716A (Research Triangle Inst., RTP, NC, 1mg/ml) and AM 251 (Cayman Chemical, Ann Arbor, MI, 1 mg/ml) and the CB 2 antagonist SR 144528 (Sanofi, Recherche, France, 1mg/ml) were prepared in an emulphor:ethanol:saline (1:1:18) vehicle and administered through the lateral vein in a volume of 1 ml/kg.
Subjects/CCI Surgery
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Sprague-Dawley rats weighing 250-350g were initially anesthetized with pentothal (50 mg/kg, i.p.) and supplemented if necessary. Forty-eight rats comprised the CCI groups, and 28 rats served as sham-operated controls. CCI was produced as follows: the right sciatic nerve was exposed at mid-thigh level immediately proximal to the point of trifurcation; it was freed from the surrounding connective tissue for a 25 mm length, and 4 chromic gut (4-0) ligatures were tied loosely around the nerve trunk. Sham-operated control animals underwent similar procedures except that no ligatures were placed around the nerve.
Behavioral testing
Heat hyperalgesia was assessed in sham-operated control and CCI rats each day after the surgery. Prior to CCI surgery, the intensity of the radiant heat stimulus was adjusted to obtain a paw withdrawal latency of approximately 10 s. Paw withdrawal latencies were recorded at 5 min intervals. Data are reported as difference scores calculated as: (latency of withdrawal of the paw ipsilateral to the CCI) -(latency of withdrawal of the paw contralateral to the CCI). Thus, negative scores indicate hyperalgesia, whereas positive scores indicate hypoalgesia. Behavioral changes were usually observed 3 days following CCI surgery and were most pronounced 7-14 days after the nerve injury as reported by Herzberg et al. (1997) . Each electrophysiology experiment was conducted immediately after behavioral testing but only if the mean difference score was in the range of -1.5 to -3.0 s. For studies of the effect of WIN 55,212-2 on neuropathic pain behavior, baseline paw withdrawal latencies were established before drug or vehicle was administered, and paw withdrawal latencies were obtained at 5 min intervals during the subsequent 25 min.
Physiological recording of single neuron responses
Each rat was anesthetized with urethane (1.5 g/kg i.p., supplemented as needed) and mounted in a stereotaxic frame. A 26 ga hypodermic needle was inserted into the lateral tail vein for subsequent drug treatments. Throughout the experiment, body temperature was held at 37°C. A laminectomy was performed at L5-L6, the spine was immobilized with clamps, and the spinal cord was bathed in warm mineral oil. Electrophysiological responses of single dorsal horn neurons with receptive fields (RFs) located on the Page 5 of 41 6 hindpaw were recorded extracellularly using tungsten parylene-coated microelectrodes (Microprobe, Potomac, MD, 0.8-1.5 M ). A microelectrode was lowered into the spinal cord using a hydraulic microdrive. Action potentials were amplified, audio monitored and discriminated according to their amplitudes. The hindpaw was brushed with a camel hair artist's brush to activate neurons that exhibited low levels of spontaneous firing. Neurons were classified as wide dynamic range (WDR), if they responded in a graded fashion to increasing intensities of mechanical stimulation (Price, 1999) .
Noxious thermal stimulation
After isolation and characterization of a neuron, the receptive field was mapped by gentle touching of the ipsilateral hindpaw with an insect pin before and after drug. A computercontrolled Peltier-device (7×7 mm) was used to rapidly heat and cool various spots of the mapped receptive fields to confirm its location and size. The thermode was positioned in contact with the hindpaw and maintained in its position throughout the experiment so that thermal-evoked responses would not be confounded with mechanical stimulation.
Stimulation trials consisted of a 2 s prestimulus interval, 20 s of thermal stimulation consisting of a linear temperature ramp from 32 to 53° C with rapid, active cooling to 32° C, which was maintained during 10s of data collection after stimulus offset. During each 32 s trial, the time of occurrence of each action potential (1 msec resolution) was recorded on a computer (Fig 1) . For each neuron, the spontaneous firing rate was assessed as the mean firing rate during the 2 s prior to stimulus onset. Evoked responses were quantified after subtracting the frequency of spontaneous discharge. Afterdischarge was quantified as the mean firing rate during the final 7 s of the trial, during which the paw temperature was maintained at 32° C. Consecutive stimulation trials were separated by 5 min to avoid peripheral and central sensitization.
Experimental procedure
Baseline responses were determined by applying the thermal stimulus 5 times at 5 min intervals. A single injection of either drug or vehicle was performed i.v., and the stimulus was applied at 5 min intervals for 25 min. In experiments that examined the receptor subtype mediating the effect of WIN 55,212-2, the subtype selective antagonist 7 SR141716A (1 mg/kg i.v. CB 1 ), AM251 (1mg/kg, i.v., CB 1 ), or SR144528 (1 mg/kg, i.v., CB 2 ) was administered 5 min before administration of WIN 55, 212-2. In one set of experiments, subsequent to recordings of baseline responses, the injured section of the nerve was bathed in 1 ml of a 0.3 mg/ml solution of WIN 55,212-2.
Histology
At the end of each experiment, a current of 20 µA was injected through the electrode (tip negative) for 15 s to mark the location of the recording site. Animals were perfused transcardially with 0.9% NaCl, followed by 10% formalin. Spinal cords were removed and stored overnight in a 30% sucrose-formalin solution. Frozen sections (40 µm) were mounted, stained with cresyl violet, and recording sites were localized microscopically.
Data analysis
The mean applied temperatures during successive time intervals in each trial were combined with the calculated firing rates to construct stimulus-response functions. Nonnoxious and noxious stimuli were defined as 32°C-45.9°C and 46°C-53°C, respectively.
The effects of drug treatment on stimulus-response functions of single neurons were determined by calculating the mean response for each subject. A C-language computer program was constructed to analyze scanned images of the paw and calculate the areas of RFs, which had been identified with an indelible marker. These data were transferred to a Hewlett-Packard (Palo Alto, CA) UNIX workstation for visualization and statistical analysis using custom C-language programs and BMDP Statistical Software (Los Angeles, CA). Multifactor repeated measures analyses of variance (ANOVA) were used to analyze treatment effects. The Greenhouse-Geiser (1959) correction was applied to interaction terms containing repeated factors to avoid inflated significance estimates produced by violations of the assumption of homogeneity of variance and covariance.
RESULTS
Effect of WIN 55,212-2 on behavioral responses of CCI rats to a thermal stimulus
Sham-operated control animals (n=23) showed no significant change in paw withdrawal latency compared to pre-surgical baseline. By contrast, decreased paw withdrawal latencies were observed following stimulation of the paw ipsilateral to the ligated nerve in CCI animals (p<0.05; n=24, Fig 2) . Prior to electrophysiology experiments (postsurgical day 8) the thermal hyperalgesia score for CCI group was -2.7 ± 0.54 s. WIN 55,212-2 (0.0625 mg/kg, 0.125 mg/kg and 0.25 mg/kg, i.v.) was administered in nerve-injured rats whose paw withdrawal latency difference scores were in the range of -1.5 to -3.0 s. The effects of WIN 55,212-2 were apparent 5 min after administration and lasted at least for 25 min. ANOVA revealed that WIN 55,212-2 dose-dependently reversed hyperalgesia in nerve-injured rats (F 8, 48 = 25.8, p<0.01, Fig 2) .
Electrophysiological characterization of spinal neurons in nerve-injured and shamoperated control rats
Fifty-six WDR neurons (33 CCI, 23 control) in L5-L6 of the spinal dorsal horn were recorded at a depth of 450-560 µm (control group: 545 ± 30 µm, CCI group: 512 ±50).
Histological reconstruction revealed that these cells were mainly located in Rexed's laminae V-VI, their receptive fields were located in the plantar surface of the paw and responded with increasing vigor to graded thermal stimulation of the RF. Hence, all neurons recorded in this study fit the classification of WDR neurons. The mean frequencies of spontaneous and afterdischarge firing of dorsal horn neurons in CCI rats were significantly higher than those of control rats (F 1,32 =95.3; p<0.05, F 1,32 =107.7, p<0.05, respectively, Table 1 ). The magnitude of both non-noxious and noxious heatevoked neuronal responses (the overall firing during the stimulation between 46°C-53°C) of CCI rats was significantly greater than that of control rats (F 1,32 =427.7, P<0.005, F 1,32 =159.4, P<0.05, respectively). As expected from previous reports (Devor and Wall, 1978) , the areas of receptive fields of WDR neurons in CCI rats were significantly larger than those of control rats (F 1,32 =49.3, p<0.005; Table 1 ). Spontaneous and evoked firing rates did not vary across baseline trails, suggesting that the stimulus parameters employed were appropriate for the determination of drug effects.
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Lack of effect of vehicle on lumbar dorsal horn WDR neurons
The vehicle was administered i.v. for each experimental condition using a separate group of animals. The electrophysiological responses (spontaneous, heat-evoked firing and afterdischarge) and receptive field areas of neurons after vehicle administration were compared to those before drug treatments by ANOVA. These analyses failed to reveal any effect of the vehicle. Because the vehicle failed to alter neuronal firing, analyses were conducted comparing pre-and post-drug treatment conditions using repeated measures ANOVA, which provides greater statistical power than between group analyses.
Effect of WIN 55, 212-2 on lumbar dorsal horn WDR neurons
Spontaneous firing
ANOVA revealed that WIN 55,212-2 (0.0625, 0.125, 0.25mg/ kg, i.v.) dose-dependently inhibited spontaneous firing in CCI rats (F 3,32 =3.75; p< 0.05, Fig 3A) . At the dose of 0.25 mg/kg, WIN 55,212-2 decreased the rate of spontaneous firing rate in CCI rats to approximately that of the control group. The significant interaction between drug treatment and lesion condition (F 3,32 =3.31; p<0.05) revealed that the drug produced a larger effect in the CCI group compared to the control group.
Experiments with the selective CB 1 antagonists SR141716A and AM251 indicated that the suppression of spontaneous firing by WIN 55,212-2 was mediated by cannabinoid CB 1 receptors. The antagonists alone did not reliably alter spontaneous firing in either control (3.9±1.5 and 4.1±2.0 Hz pre-and post-drug, respectively) or CCI (18.8±3.6 and 21.4±2.5 Hz pre-and post-drug, respectively) group. Pretreatment with either SR141716A or AM251 blocked the suppression induced by WIN 55,212-2 in CCI groups (F 1,4 = 47.39; p<0.05, Fig 3B) . There was no significant difference between the two CB 1 antagonists (p>0.05). By contrast, the CB 2 antagonist SR144528 did not alter the suppression of spontaneous firing by WIN 55,212-2 in nerve injured rats (P>0.05, Fig.   3B ). These data indicate that CB 1 receptors mediated the suppressive effects of WIN 55,212-2 on spontaneous firing.
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Heat-Evoked Firing
The stimulus-response functions of neurons recorded in CCI rats were left-shifted compared to those of control rats, and the magnitude of the noxious heat evoked response of neurons recorded in CCI rats was significantly greater than that of control rats (F 1,32 =83.6, P<0.005; Fig 4) . These observations are consistent with the observations of allodynia and hyperalgesia in nerve injured rats.
WIN 55,212-2 decreased both non-noxious and noxious heat-evoked activity of spinal neurons in CCI rats (F 3, 32 =74.37, p<0.05; F 3, 32 = 45.90, p<0.05, respectively; .
At the dose of 0.125 mg/kg, WIN 55,212-2 normalized the responses of the neurons to noxious heat stimuli in CCI rats by right shifting the curve to overlap with that obtained from untreated control rats ( Fig 4B) . In contrast, the effects of WIN 55,212-2 on stimulus-response functions of control rats occurred only at higher doses. At dose s that suppressed neuronal responses of both CCI rats and control rats, the degree of suppression was greater in CCI rats compared to control rats. The heightened potency and efficacy of WIN 55,212-2 in CCI rats suggests that nerve injury leads to sensitization of the endocannabinoid system.
When administered alone, neither of the CB 1 antagonists (SR141716A, AM251) altered noxious thermal evoked responses in either control (15.9±3.9 and 16.6±6.0 Hz for preand post-drug, respectively) or CCI (43.76±8.59 and 37.36±7.49 Hz pre-and post-drug, respectively) rats. However, the suppression by WIN 55, 212-2 of heat evoked-responses in CCI rats was blocked by pretreatment with either SR141716A or AM251 (F 1,4 =479.03; p<0.005), indicating a cannabinoid CB 1 receptor-mediated effect ( Fig 6B) . There was no significant difference in efficacy between the two CB 1 antagonists (p>0.05). By contrast, the CB 2 antagonist SR144528 failed to alter the ability of WIN 55, 212-2 to suppress the responses of neurons in CCI rats (P>0.05, Figure 6B ).
Afterdischarge
Page 10 of 41 ANOVA revealed that WIN 55,212-2 dose-dependently decreased afterdischarge in spinal neurons of CCI rats (F 3,32 =6.4; p< 0.05, Fig 7A) . Similar effects in control rats were found only at higher doses. WIN 55,212-2 produced a larger suppression of afterdischarge in CCI rats as compared to that of control rats (F 3,32 =5.4; p<0.05).
As with the other dependent measures, the suppressive effects of WIN 55, 212-2 on afterdischarge were blocked by pretreatment with either SR141716A or AM251 in CCI rats (F 1,4 =49.4; p<0.05), indicating that the effect was mediated by CB 1 receptors ( Fig   7B) . No significant difference was found between the two CB 1 antagonists. The antagonists alone did not alter the afterdischarge of neurons recorded from either control (4.7±3.8 and 4.5±2.8 Hz pre-and post-drug, respectively) or CCI (22.8±4.7 and 16.4±5.9
Hz pre-and post-drug, respectively) rats. The CB 2 antagonist SR144528 failed to produce a significant change in the actions of WIN 55,212-2 (p>0.05, Figure 7B ).
Receptive Field Size
The areas of the receptive fields of neurons recorded in CCI rats were significantly larger than those of control rats (F 1,32 =49.3, p<0.005). WIN 55,212-2 dose-dependently decreased the sizes of receptive fields of WDR neurons in both control and CCI rats (F 3,32 =3.9; p< 0.05, Fig 8A) . The decrease in receptive field size was clear at the dose of 0.125 mg/kg WIN 55,212-2, and ANOVA revealed a larger effect in CCI rats as compared to control rats (F 3,32 =4.7; p<0.05). The suppressive effect of WIN 55,212-2 on receptive field size was blocked by pretreatment with either SR141716A or AM251 in both control and CCI groups (F 1,4 =279.6; p<0.005, F 1,4 =328.4; p<0.005), indicating that the effects were mediated by CB 1 receptors ( Fig 8B) . There was no significant difference between the two CB 1 antagonists (p>0.05). The antagonists alone did not alter receptive field size in either control (118.6 ±13.8 and 125.5±16.8 mm 2 pre-and post-drug, respectively) or CCI (142.8±17.4 and 158.4±15.5 Hz pre-and post-drug, respectively) rats. The CB 2 antagonist SR144528 failed to block the reduction in receptive field size by WIN 55, 212-2 in CCI rats ( Figure 8B ).
Time course of the effect of WIN 55, 212-2 in control and CCI rats
Page 11 of 41 WIN 55,212-2, at the dose of 0.125 mg/kg, significantly suppressed noxious heat-evoked activity of neurons in both control and CCI rats, with greater effects in CCI rats (F 3,32 = 5.89, p<0.01). Throughout the 25 min interval of recording, the suppression of evoked firing produced by WIN 55,212-2 in CCI rats was maintained (Fig 9) . In contrast, control rats recovered from the suppression 20 min after drug injection (Fig 9) .
Site of action of WIN 55, 212-2 in CCI rats
When directly administered around the injured sciatic nerve, WIN 55,212-2 (1 ml, 0.3 mg/ml = 574 µM bathing solution) failed to alter noxious heat-evoked firing rates (p>0.05, compared to 0.25 mg/kg i.v., Figure 10 ). In Chinese hamster ovary (CHO) cells overexpressing human CB 1 or CB 2 receptors, WIN 55,212-2 was reported to have Ki values of 1.9 nM and 0.3 nM, respectively. The lack of effect of the high dose used, which was employed to ensure full activation of CB 1 and CB 2 receptors in the vicinity of the injury site, strongly suggests a site of action other than the injury site.
Relationships among Neurophysiological Indices and Behavioral Responses.
As noted above, CCI rats withdrew their paws from a radiant thermal stimulus with a shorter latency than that of sham-operated control rats.
Comparison of the neurophysiological and behavioral dose curves of WIN 55,212-2 in CCI rats may provide insight into the critical determinants of the abnormal sensitivity to thermal stimuli in nerve injury. A cursory examination shows that the behavioral response showed a major change towards normalcy at the dose of 0.125 mg/kg, specifically a 37% change from the next lower dose, 0.0625 mg/kg. By contrast, the changes in spontaneous firing and nonnoxious heat-evoked firing were only 11% and 5% respectively. Correlations between the dose curves of the behavioral and the neurophysiological indices revealed a 0.95 correlation between paw withdrawal latency and receptive field size and a 0.89 correlation for behavior and neurophysiological response at noxious temperatures.
Although the latter correlation is difficult to explain, because the animals never experienced these temperatures in the behavioral testing paradigm, the strong correlation between receptive field size and behavior suggests that the exaggerated population 
DISCUSSION
Confirming previous reports (Palecek et al., 1992a,b; Sotgui et al., 1995; Pertovaara et al., 1997; Devor and Wall, 1978, Chapman, 2001) , this study showed that WDR neurons studies showed CB 2 expression in the dorsal root ganglion (Ross et al., 2001; Beltramo et al., 2006) and the superficial laminae of the spinal cord following peripheral nerve injuries probably associated with activated microglia (Zhang et al., 2003; Wotherspoon et al., 2005) . In the current study, systemic administration of the CB 2 receptor antagonist SR144528 failed to reduce any of the effects of WIN 55,212-2 suggesting a CB 1 receptor-mediated effect. The lack of CB 2 mediated effects cannot be explained in terms of the selectivity of WIN 55,212-2, because it is approximately 20-fold more potent at CB 2 compared to CB 1 (Showalter et al., 1996) . Furthermore, Herzberg et al. (1997) reported that SR141716A reversed the effect of WIN 55,212-2 in a behavioral study of neuropathic pain, and the increased potency of WIN 55,212-2 in neuropathic pain may be explained by the up-regulation of CB 1 receptors in contralateral thalamus and ipsilateral spinal dorsal horn following nerve injury (Siegling et al, 2001; Lim 2003) .
The up-regulation of CB 1 receptors by nerve injury may also explain why WIN 55,212-2 produced greater inhibition of spontaneous firing, noxious stimulus-evoked responses, afterdischarge and receptive field size in CCI rats compared to control rats. The enhanced sensitivity to cannabinoids in nerve-injured rats reported here is consistent with reports that anti-hyperalgesic and anti-allodynic effects of WIN 55,212-2 occurred at doses that did not affect pain-related behavior under non-pathological conditions (Herzberg et al., 1997; Richardson et al., 1998; Fox et al., 2001; Bridges et al., 2001) . This enhanced sensitivity may be selective for nociception because we did not observe behavior indicative of psychotropic effects (e.g., sedation) at the any of doses of WIN 55,212-2 used, an observation consistent with previous studies (Herzberg et al., 1997) .
Examination of the dose-curves of WIN 55,212-2 in measures of pain behavior in comparison to those of the various electrophysiological parameters suggests the relative importance of particular neurophysiological anomalies in the maintenance of neuropathic pain. In considering this issue, it should be noted that skin temperature rises steadily as a logarithmic function of the duration of application of a fixed source of radiant heat (Hargreaves et al., 1988) . Hence, treatments that reduce the paw withdrawal latency indicate the occurrence of a behavioral response at a temperature lower than normal.
Hence, any neurophysiological effects of WIN 55,212-2 on temperatures above the normal thermal pain threshold are irrelevant because in the behavioral experiments, these temperatures were not reached due to paw withdrawal. In attempting to understand how the neurophysiological parameters correspond to pain perception following treatment with the cannabinoid, of particular note was the contrast between the doses of 0.0625 mg/kg and 0.125 mg/kg WIN 55,121-2. The lower dose produced virtually no effect on pain behavior, whereas the higher dose resulted in virtually normal pain behavior. Only one of the relevant neurophysiological variables, receptive field size, showed a highly similar dose-response relationship. A marked decrease (normalization) in receptive size occurred between the two doses, and the size of the receptive field exhibited a 0.95 correlation with the behavioral response. By contrast, there was little difference between the effects of the two doses on stimulus-evoked firing rate at temperatures below 46º C.
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Similarly, the effects of the cannabinoid on spontaneous firing at the doses 0.0625 and 0.125 mg/kg were small and similar in magnitude. The observation that the doses that reduced injury-induced exaggeration of receptive field size were the same as those that caused a normalization of pain behavior suggest that it is the larger population response of spinal neurons resulting from nerve injury that accounts for the decreased withdrawal latencies to a thermal stimulus in CCI rats. Conversely, these findings suggest that in subjects with painful neuropathy, a treatment that reduces the sizes of the receptive fields of spinal WDR neurons may markedly reduce the perception of thermal pain, even if the treatment fails to affect spontaneous firing rate or magnitude of evoked firing in response to non-noxious temperatures.
The implications of the data discussed above deserve a rigorous test in future experiments, especially because of factors that limit interpretation of the present data.
First, the electrophysiological experiments were conducted with a contract thermode that produced a controlled temperature ramp, whereas the behavioral experiments were conducted with a fixed source of radiant heat. Previously reported differences in psychophysical stimulus-response functions for contact heat versus radiant heat (reviewed by Price, 1988) and the presence of mild mechanical stimulation due to placement of the contact thermode limit the ability to generalize between the two experimental conditions. Second, the electrophysiological experiments were conducted in anesthetized animals, whereas the behavioral experiments were conducted in waking animals. The generality of results obtained from anesthetized subjects to those of awake subjects is uncertain. Finally, while this study focused on thermal stimulation, future studies would benefit from comparing thermal and mechanical stimuli, as the mechanisms for thermal hyperalgesia and mechanical allodynia likely differ.
Nevertheless, a working hypothesis for future investigations may be gained from the present experiments, and cannabinoid agonists may be a useful tool for such investigations because of the demonstration of different dose requirements for altering the various physiological aberrations in neuropathic pain.
In this study, pretreatment with either SR141716A or AM251 did not change the responses of WDR neurons in either CCI or control rats. This contrasts with the previously reported observation that administration of SR141716A alone increased allodynia and hyperalgesia in rats with peripheral nerve injury (Herzberg et al., 1997 , but see Bridges et al., 2001 . The increased pain-related behavior after administration of these receptor antagonists suggested endocannabinoid tone in neuropathic pain.
Alternatively, these observations may be the result of inverse agonism by the compounds.
Although several reports suggested the presence of a physiological analgesic tone exerted by the endocannabinoid system (Richardson et al., 1998; Martin el al., 1999; Strangman et al., 1999) , others investigators failed to observe enhancement of pain subsequent to administration of SR141716A (Bridges et al., 2001; Rinaldi et al., 1995; Beaulieu et al., 2000) suggesting that endocannabinoid modulation of pain has multiple controls.
In contrast to the findings in this experiment, Chapman (2001) reported that systemically administered cannabinoids did not significantly reduce electrically-evoked responses of spinal neurons in nerve-injured rats. The different results of the two experiments may be due to the use of natural stimuli in the present study, whereas electrical stimuli were used in the previous study.
Recent evidence suggested the existence of a novel non-CB 1 , non-CB 2 cannabinoid receptor (Di Marzo et al., 2000; Breivogel et al., 2001) . This putative G protein-coupled receptor can be activated by anadamide and WIN 55,212-2 but not by other CB 1 /CB 2 agonists, and the cannabinoid antagonist SR141716A does not distinguish between the canonical CB 1 and the putative new CB receptor (Hoffman and Lupica, 2000; Hajos et al., 2001) . However, the selective CB 1 antagonist AM251 (2µM) blocked WIN 55,212-2induced inhibition of evoked IPSCs, but not of EPSCs, in the hippocampus providing evidence for its ability to separate CB 1 from the new CB receptor (Hajos and Freund, 2002) . In our experiment, the effect of AM251 was not significantly different from that of SR141716A, further suggesting a CB 1 -mediated effects. 
